. 2012 Feb 10;42(4):287–294. doi: 10.1093/jjco/hys005

Table 1.

Patient characteristics and clinical use

	n	%
(A) Patient characteristics
Sex
Male	1234	61.5
Female	772	38.5
Age
<65 years	1032	51.4
≥65 years	971	48.4
Unknown	3	0.2
Tumour site (including overlapping sites)
Colon	1235	61.6
Rectum	775	38.6
PS
0	1370	68.3
1	630	31.4
2	2	0.1
Unknown	4	0.2
Treatment line
Second line	133	6.6
Third line and later treatment	1869	93.2
Others	4	0.2
Previous chemotherapy
(−)	3	0.2
(+)	2003	99.9
FOLFIRI	1510	75.3
FOLFOX	1854	92.4
5-FU/LV	370	18.4
Irinotecan	261	13.0
UFT/LV	337	16.8
Bevacizumab	923	46.0
Previous surgery
(−)	81	4.0
(+)	1925	96.0
Previous radiation therapy
(−)	1650	82.3
(+)	355	17.7
Unknown	1	0.0
EGFR-IHC
Positive	1974	98.4
Negative	29	1.4
Not tested	3	0.2
KRAS status
Wild	249	12.4
Mutant	53	2.6
Not tested	1691	84.3
Unknown	13	0.7
Comorbidity
(−)	1019	50.8
(+)	974	48.6
Unknown	13	0.6
(B) Clinical use
No. of treatments
<4	253	12.6
4 to <16	900	44.9
16 to <32	524	26.1
32 to <48	255	12.7
≥48	74	3.7
Duration of treatment
<4 weeks	276	13.8
4 to < 16 weeks	739	36.8
16 to <32 weeks	489	24.4
32 to <48 weeks	280	14.0
≥48 weeks	222	11.1
Cumulative dose
<1500 mg/m²	435	21.7
1500 to <3000 mg/m²	493	24.6
3000 to < 9000 mg/m²	832	41.5
≥9000 mg/m²	236	11.8
Unknown	10	0.5
Combination chemotherapy
(−)	460	22.9
(+)	1546	77.1
Irinotecan	1255	62.6
FOLFIRI	256	12.8
Others	35	1.7
Combination radiation therapy
(−)	1943	96.9
(+)	59	2.9
Unknown	4	0.2
Pre-medication^a
No	14	0.7
Antihistamine alone	185	9.2
Corticosteroid alone	23	1.2
Antihistamine + corticosteroid	1783	88.9

PS, performance status; 5-FU, 5-fluorouracil; LV, leucovorin; UFT, tegafur-uracil; EGFR, epidermal growth factor receptor; IHC, immunohistochemistry.

^aExcluded unknown (one patient).